Your first 90 days
Your first 90 days on Papzimeos for recurrent respiratory papillomatosis
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Papzimeos is a medicine for recurrent respiratory papillomatosis that works alongside surgery instead of replacing it at the start. The plan begins with an operation to clear the visible papillomas, then 4 injections under the skin over 12 weeks. Each injection is prepared from a frozen vial and given by a healthcare professional. This page lays out those first 3 months from the FDA label, the approval letters and Precigen's own program pages.
What has to happen before the first bottle ships
The FDA approval letter sets no REMS requirement for Papzimeos, and it is given by a healthcare professional, never taken at home. The first dose waits on surgery, a site that can store the frozen vials and an insurance decision. These are the 6 things in the way, in order.
Surgery to clear the visible papillomas
The label says to remove the papillomas that can be seen before the first dose, leaving as little disease as possible.
- Doctors call this operation surgical debulking, the first step in the Papzimeos plan.
- The label does not set how many days before dose 1 it should happen, and in the trial the surgery was on the same day as dose 1.FDA label
A site that can store and give it
Papzimeos arrives frozen, and the label says to keep it at minus 76 degrees Fahrenheit or colder until use.
- Precigen says your ENT may need to work with other specialists and facilities that can store and give it.
- Precigen's patient site has a site locator for places that give Papzimeos.Precigen patient site
The Papzimeos SUPPORT enrollment form
Precigen says access to Papzimeos starts with the Papzimeos SUPPORT Enrollment Form, which the doctor's office completes.
- The office needs your clinical history, your insurance details and the site where you will get the injections.
- After the online form is sent, Precigen's page says a company it calls Biologics contacts you for your signature.Precigen prescriber site
An insurance decision
Precigen's ordering guide says orders are filled once the insurer approves the prescription.
- The example policy on this page asks for a pathology report and 3 or more surgeries in the last 12 months.
- Your own plan may ask for something different, so the office checks with it.Precigen ordering guide
The vial ordered in time
Precigen's ordering guide asks clinics to place the order at least 2 weeks before the planned injection.
- It says delivery takes 2 to 3 business days, on Tuesday through Friday.
- Each of the 4 doses comes as its own single-dose vial.Precigen ordering guide
Your health history
Precigen's safety information says to tell your healthcare provider about all of your medical conditions before treatment.
- That includes being pregnant, planning a pregnancy, breastfeeding or planning to breastfeed.
- The label says there are no data on Papzimeos in pregnant women.Papzimeos SUPPORT
The days that matter
Counted from the first dose, with the surgery before it and doses at weeks 2, 6 and 12. The label judges the result over the year after treatment. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Enrollment and the insurance review
The doctor's office sends the Papzimeos SUPPORT Enrollment Form, and the program checks your benefits.
- Precigen says the program then tells the prescriber what your insurer requires.
The clinic orders the first vial
Precigen's ordering guide asks clinics to order at least 2 weeks before the planned injection.
- Orders are filled once the insurer has approved the prescription.
Surgery to clear the visible papillomas
The label calls for this surgery before the first dose and sets no number of days between them.
- In the trial, the label says, the protocol's debulking surgery was on day 1.
Dose 1, an injection under the skin
A healthcare professional thaws the vial and injects 1mL under the skin of the outer upper arm or thigh.
- The label says you are watched for at least 30 minutes after this first dose.
The injection site and how you feel
Redness, pain, swelling, itching or warmth at the site are the reactions the label describes.
- Tiredness, chills and fever were also common in the trial.
- The label says to seek care if site symptoms get worse or come with trouble breathing, a widespread rash, facial swelling or signs of infection.
Dose 2, 2 weeks after the first
The label schedule puts the second dose 2 weeks after the first.
- It also says the second dose should come no less than 11 days after the first.
Dose 3, at week 6
The third dose comes 6 weeks after the first, by the label schedule.
- Before it, the label says to remove any visible papilloma, if present.
Dose 4, the last one
The fourth dose comes 12 weeks after the first and completes the label course.
- The label again says to remove any visible papilloma, if present, before this dose.
Follow-up and the 12-month mark
The label judged Papzimeos by whether people needed any surgery in the 12 months after treatment.
- The label sets no follow-up visit schedule, which leaves the timing to your otolaryngologist.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Papzimeos label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated August 12, 2025, read from the FDA's label database today. FDA label
- November 2026
DailyMed's page for Papzimeos did not load for us on November 11, 2026. This page was read from the FDA's own label record, dated August 12, 2025, and the package insert on the FDA product page.FDA product page
- February 2026
The FDA approved a supplement on February 25, 2026 for administrative changes to the prescribing information. The package insert on the FDA product page still reads Revised 08/2025, and its dosing and warnings match the label record.FDA supplement letter
- August 2025
The approval letter requires Precigen to send blood clot reports to the FDA within 15 days, for 3 years after approval. Precigen also committed to a viral shedding study and a study in children.FDA approval letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- Given by a healthcare professional
Papzimeos is not a medicine you take at home or inject yourself.
- Precigen's patient site says it can only be given by a healthcare professional.
- The label says it is for injection under the skin only.Precigen patient site
- Four doses over 12 weeks
The label dose is 1mL under the skin, given 4 times, at the start and then 2, 6 and 12 weeks later.
- The label describes no second course after the fourth dose.FDA label
- Surgery can still happen during the course
The label says to remove any visible papilloma, if present, before the third and fourth doses.
- Precigen's patient site says you may need another surgery before your third or fourth dose, or both.FDA label
- If a dose is missed or late
The label gives no instruction for a missed or late dose.
- Its only timing rule is that dose 2 comes no less than 11 days after dose 1.
- Ask the clinic what its plan is before the first dose.FDA label
- The injection site for the first day
The label says to avoid direct contact with the injection site and its dressings for about 24 hours.
- Touching and scratching the site are the examples of contact that it gives.
- It also tells the person giving the shot not to massage the site.FDA label
- Dressings and hand washing for 1 to 2 weeks
The label says used dressings from the injection site go in a sealable bag, then into regular trash.
- It asks for these precautions for 1 to 2 weeks after each injection.
- It also calls for hand washing after direct contact with the patient's body waste.FDA label
- What is known about shedding
Papzimeos is made from an adenovirus that cannot make copies of itself.
- The label says no studies have measured whether it is shed from the body.
- Precigen has committed to the FDA to run a shedding study, with the report due by December 31, 2026.FDA approval letter
- Other medicines
The label has no drug interactions section and lists no medicines to avoid.
- The trial left out people who needed steroid pills or shots above 10mg of prednisone a day, or other immune-suppressing medicines, within 14 days of dosing.
- Inhaled and topical steroids were allowed.
- Ask the otolaryngologist how the medicines you take fit with the Papzimeos plan.ClinicalTrials.gov
- Pregnancy and breastfeeding
The label says there are no data on Papzimeos in pregnant women, and no animal pregnancy studies were done.
- It has no information on whether Papzimeos passes into breast milk.
- Any decision about Papzimeos in pregnancy or breastfeeding rests with you and the otolaryngologist.FDA label
- Age limits in the label
Papzimeos is approved for adults with recurrent respiratory papillomatosis, not for children.
- The label says safety and effectiveness in children have not been established.
- The trial had too few people aged 65 or older to tell whether they respond differently.FDA label
- Storage is the clinic's job
The clinic keeps Papzimeos in a freezer at minus 76 degrees Fahrenheit (minus 60 Celsius) or colder.
- The label says a thawed vial is not held at room temperature for more than 60 minutes.
- A thawed vial never goes back into a refrigerator or freezer.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Injection site reactions
Redness, pain, swelling, itching or warmth where the shot went in are the signs the label lists.
- The label says to seek medical care if these get worse, or come with signs of infection.
- It says the same for trouble breathing, a widespread rash or facial swelling, which can mean a body-wide allergic reaction.FDA label
Blood clots
The label warns that blood clots may occur after adenovirus-based treatments, including Papzimeos.
- The signs it lists are shortness of breath, chest pain, leg swelling, lasting belly pain, severe or lasting headaches and blurred vision.
- Precigen's safety information says to notify your doctor immediately about any of these.
- The label does not say how long after an injection this can happen.FDA label
The most common side effects
In the trial of 38 adults, injection site reactions affected 97%, tiredness 74%, chills 66% and fever 63%.
- Muscle aches affected 29% of people, nausea 26% and headache 11%.
- A fast heart rate affected 8%, and diarrhea, vomiting and heavy sweating 5% each.FDA label
Less common reactions
The label also lists blurred vision, bruising at the injection site, dizziness, shortness of breath and itching.
- Each of these affected 3% of trial patients, about 1 in 38 people.
- No reaction in the trial was graded higher than grade 2.FDA label
Easing a sore injection site
The label has providers advise cold compresses, over-the-counter pain relievers or antihistamines for site symptoms, if needed.
- Ask your care team which of these fits you before the first dose.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedThe example FEP Blue policy asks for a pathology report and papillomas in the larynx or windpipe. It also asks for 3 or more debulking surgeries in the last 12 months, a number the label does not require. Precigen says Papzimeos SUPPORT gives information on prior authorization and helps with appeals when it is the specialty pharmacy.FEP Blue policy
- A request for a second courseThe example FEP Blue policy allows only one approval, for 4 injections per lifetime, and has no renewal. The label describes a course of 4 doses and no retreatment course after it.FEP Blue policy
- The clinic cannot store itThe label requires storage in a freezer at minus 76 degrees Fahrenheit or colder until the vial is thawed. Precigen says your ENT may need to work with other specialists and facilities that can store and give Papzimeos. Precigen's patient site has a site locator for places that give it.Precigen patient site
- The vial was not ordered or approved in timePrecigen's ordering guide asks for orders at least 2 weeks before the planned injection. It says orders are filled once the insurer has approved the prescription, so the approval comes first.Precigen ordering guide
- A cost question on Medicare, Medicaid or other government insurancePrecigen's copay program is only for people with commercial insurance. Its terms exclude Medicare, Medicaid, VA, Department of Defense and TRICARE coverage. Precigen's patient site says Papzimeos is covered by Medicare and Medicaid, and Papzimeos SUPPORT can explain your costs.Precigen prescriber site
- The patient is under 18The label covers adults only, and the example FEP Blue policy requires age 18 or older. Precigen has committed to the FDA to study Papzimeos in children, with a final report due by December 31, 2028.FDA approval letter
FEP Blue (Blue Cross and Blue Shield Federal Employee Program) prior authorization policy, effective July 1, 2026
- Age 18 or older
- A diagnosis of recurrent respiratory papillomatosis
- A histological diagnosis of papilloma confirmed by a pathology report
- Papillomas present in the larynx or windpipe (laryngotracheal papillomas)
- A history of 3 or more debulking procedures to remove laryngotracheal papillomas in the last 12 months
- The prescriber agrees to monitor for injection site reactions and blood clots (thrombotic events)
Approval length. One approval for 4 vials, the 4 injections, per lifetime, with no renewal. The policy does not state a length of time for the approval.
FEP policy 5.01.081 was first written on October 24, 2025 and last reviewed on June 11, 2026. It cites the August 2025 package insert, the same label used on this page. Its surgery count matches who the trial enrolled, while the label covers adults with the condition and names no number of surgeries. Other plans set their own rules, which can differ from this example. FEP Blue policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- Help with the insurance process and the information your health plan may need
- A copay program that may bring out-of-pocket cost to as little as $0 for eligible people with commercial insurance, with no income requirements
- A representative who tracks your enrollment, with automatic review for the copay program if your copay is high
- Precigen says Papzimeos is covered by Medicare and Medicaid, and that coverage is growing
- The copay program terms exclude Medicare, Medicaid, VA, Department of Defense and TRICARE coverage, and anyone getting help from another program or foundation Precigen prescriber site
- The copay program helps only with the cost of Papzimeos and giving it, up to a program maximum that the page does not state Precigen prescriber site
- Precigen's exclusive specialty pharmacy runs the program and can order the vial and arrange delivery to the site of care Precigen ordering guide
- No free drug or bridge program is described on the pages we read on November 11, 2026
Details as the drugmaker publishes them. Papzimeos SUPPORT
Five questions for the pharmacist or the support line
- Where will I get the injections, and does that site have the ultra-cold freezer Papzimeos needs?
- When will my debulking surgery be, and how soon after it will dose 1 be given?
- Who checks my airway before doses 3 and 4, and what happens if papillomas are seen?
- What is the plan if a dose has to be moved or is missed?
- Has my plan approved all 4 doses, and what will I owe for each visit?
- Who do I call after hours about the injection site or signs of a blood clot?
Questions people ask in the first weeks
How is Papzimeos given?
Papzimeos is a 1mL injection under the skin of the outer upper arm or thigh, given by a healthcare professional. The vial is stored frozen and thawed just before the injection. The label says you are watched for at least 30 minutes after the first dose.
How many doses of Papzimeos are there?
The label schedule is 4 doses over 12 weeks, at the start and then 2, 6 and 12 weeks later. The second dose should come no less than 11 days after the first. The label does not describe a second course after the fourth dose.
Do I need surgery before Papzimeos?
Yes, the label says to remove the visible papillomas before the first dose. It also says to remove any visible papilloma, if present, before the third and fourth doses. The label sets no number of days between the surgery and a dose.
Does Papzimeos have a boxed warning?
No, the August 2025 label has no boxed warning and lists no contraindications. Its 2 warnings cover injection site reactions and blood clots, which may occur after adenovirus-based treatments.
What are the side effects of Papzimeos?
In the trial of 38 adults, the most common were injection site reactions in 97% and tiredness in 74%. Chills affected 66%, fever 63%, muscle aches 29% and nausea 26%. No reaction in the trial was graded higher than grade 2.
How well did Papzimeos work in the trial?
The label counted 35 adults who had needed 3 or more surgeries in the year before treatment. Eighteen of them, 51%, needed no surgery in the 12 months after treatment. Fifteen of those 18 still needed no surgery at 24 months.
Can I take Papzimeos at home?
No, Precigen's patient site says Papzimeos can only be given by a healthcare professional. The vials need a freezer at minus 76 degrees Fahrenheit or colder, so the site of care stores them.
Will my insurance cover Papzimeos?
Each plan sets its own rules, and Precigen says coverage is broad across plans. The example FEP Blue policy asks for a pathology report and 3 or more debulking surgeries in the last 12 months. Papzimeos SUPPORT, at 1-866-827-8180, helps with the insurance process and the information your health plan may need.
Free email alert
Hear when the Papzimeos label changes
One email the day the FDA revises the Papzimeos label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Papzimeos only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Recurrent respiratory papillomatosis for new trials, FDA decisions and label changes for every treatment.
Sources
- Package Insert - PAPZIMEOS (zopapogene imadenovec-drba) suspension for subcutaneous injection, Revised 08/2025, FDA, Center for Biologics Evaluation and Research, August 12, 2025.
- PAPZIMEOS, FDA, Center for Biologics Evaluation and Research, March 2, 2026.
- August 14, 2025 Approval Letter - PAPZIMEOS, FDA, Center for Biologics Evaluation and Research, August 14, 2025.
- February 25, 2026 Approval Letter - PAPZIMEOS, FDA, Center for Biologics Evaluation and Research, February 25, 2026.
- FDA Approves First Immunotherapy for Recurrent Respiratory Papillomatosis, FDA, August 14, 2025.
- Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis, Precigen, August 15, 2025.
- Access & Support | PAPZIMEOS® (zopapogene imadenovec-drba), Precigen, November 11, 2026.
- Why PAPZIMEOS? | Starting PAPZIMEOS® (zopapogene imadenovec-drba), Precigen, November 11, 2026.
- PAPZIMEOS (zopapogene imadenovec-drba) Navigating Access, Precigen, November 11, 2026.
- Distribution and Product Ordering Guide: Information to Help You With Ordering and Receiving PAPZIMEOS, Precigen, September 1, 2025.
- 5.01.081 Papzimeos, Blue Cross Blue Shield Association, Federal Employee Program, July 1, 2026.
- Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis, NCT04724980, ClinicalTrials.gov, record verified June 2025, November 11, 2026.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing otolaryngologist. Found an error? Use the report link in the footer and it will be checked against the source.